May 02, 2026 a 08:38 am
GILD: Analysts Ratings - Gilead Sciences, Inc.
Gilead Sciences, Inc. showcases a strong position in the biopharmaceutical sector, with its diverse portfolio addressing crucial healthcare needs. Recent analyst ratings indicate sustained confidence in the company, with a significant number of "Buy" recommendations. As Gilead continues to focus on unmet medical needs, its potential for growth remains robust, although market dynamics warrant careful monitoring.
Historical Stock Grades
| Rating | Number | Score |
|---|---|---|
| Strong Buy | 5 | |
| Buy | 17 | |
| Hold | 8 | |
| Sell | 0 | |
| Strong Sell | 0 |
Sentiment Development
The sentiment around Gilead Sciences indicates a modest increase in "Buy" ratings over recent months, while "Strong Buy" ratings have shown stability. The consistent "Hold" ratings suggest a cautious but optimistic view among analysts. Rating trends reveal:
- Stable interest in Strong Buy recommendations over the past year.
- Fluctuations in Buy ratings, peaking in recent months.
- Hold ratings have slightly decreased, reflecting potential market confidence.
Percentage Trends
Analyst recommendations for Gilead Sciences have seen shifts, with a relative push towards buy categories, suggesting increasing confidence. Analysis over time highlights:
- An upward trend in Buy ratings from November to May.
- A subtle decline in Hold ratings, indicating positive sentiment.
- No significant movement in Sell or Strong Sell, reflecting stability in bearish perspectives.
Over the last year, the market has shown increased optimism, likely due to Gilead's consistent performance and strategic partnerships.
Latest Analyst Recommendations
| Date | New Recommendation | Last Recommendation | Publisher |
|---|---|---|---|
| 2026-04-13 | Buy | Buy | Citigroup |
| 2026-04-10 | Overweight | Overweight | Morgan Stanley |
| 2026-02-23 | Buy | Buy | Needham |
| 2026-02-11 | Sector Perform | Sector Perform | RBC Capital |
| 2026-02-11 | Overweight | Overweight | Cantor Fitzgerald |
Analyst Recommendations with Change of Opinion
| Date | New Recommendation | Last Recommendation | Publisher |
|---|---|---|---|
| 2025-08-08 | Buy | Hold | Truist Securities |
| 2025-07-25 | Buy | Hold | Needham |
| 2025-02-18 | Buy | Hold | Deutsche Bank |
| 2025-01-10 | Overweight | Equal Weight | Morgan Stanley |
| 2024-11-08 | Hold | Buy | Maxim Group |
Interpretation
The prevailing consensus among analysts on Gilead Sciences reflects a generally positive market outlook, characterized by strong "Buy" and "Overweight" recommendations. While stability in "Hold" ratings suggests some caution, recent upgrades indicate growing confidence. There appears to be a solid underpinning in analysts' perspectives, with few shifts towards bearish opinions, highlighting a stable outlook amidst potential market volatilities.
Conclusion
Gilead Sciences, Inc. remains a reliable player within the biopharmaceutical industry, showcasing robust growth catalysts through its diverse therapeutic portfolio. Analysts' recommendations have shifted favorably over recent months, increasing confidence in the stock’s potential. However, given the complex nature of healthcare markets, volatility and changing regulations pose risks. Overall, the enduring analyst confidence, marked by consistent buy-related recommendations, underscores a positive outlook for investors.
Smart Data Insight
Master the Perfect Entry & Exit for this Stock
Don't leave your profits to chance. Historically, this stock follows specific seasonal patterns that institutional traders use to maximize returns.
- ✅ Identify the "Golden Buying Window"
- ✅ Avoid high-risk correction cycles
- ✅ Backtested data from the last 20+ years